One of the traders in this guide called the 2008 crash live from the NYSE floor on CNBC. It's still on YouTube.

Another manages a 7-figure personal book every day and says most traders would make more money doing less.

A third uses a framework from the 1930s that most modern traders have never heard of. It still works.

The other two? A former accountant who trades nothing but gaps. And an options income trader who sold his trading company — twice.

T3 Live asked all five the same question: "If a trader could only read one chapter of advice from you — what would you write?"

The result is The Trader's Bible. 7 chapters. Small account growth, options, gap trading, earnings, Wyckoff price action, income strategies. Written from the content of the traders themselves.

Get your copy of The Trader's Bible here

T3 Live

P.S. — Sami's 5-point gap scoring system alone is worth your time. I've never seen anyone else teach it this way.

Up Over 200% in 2026, What's Next for AI Stock Aehr Test Systems?

By Leo Miller. Published: 4/10/2026.

Aehr Test Systems (NASDAQ: AEHR), a small company in the semiconductor industry, has been indisputably one of the market’s best performers of 2026. During the year, AEHR is one of just five stocks in the Russell 3000 Index to deliver a return of more than 200%.

Understanding the scope of the Russell 3000 helps put this into perspective. The index measures the performance of the 3,000 largest U.S. stocks, representing around 98% of the investable U.S. equity market. Because of this, many consider the Russell 3000 to be the most comprehensive gauge of the U.S. stock market. That underscores just how notable Aehr’s performance has been in 2026.

The company makes equipment used to stress-test semiconductors and has announced multiple deals this year. Despite mixed results in its latest earnings report, the stock jumped nearly 26% afterward. Here’s what’s driving Aehr’s explosive gains and what investors should consider going forward.

Silicon Photonics Deal Boosts AEHR Stock

URGENT: $2 Gold Stock With Major Discovery (Ad)

A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1 trillion.

According to Jim Rickards, an announcement is expected around July 1 that could bring this historic discovery into public view.

See the full details on this $2 gold stock before July 1

Most of Aehr’s 2026 gain occurred in a span of less than two weeks. The stock began the year near $20, climbed to about $30 by late March, and then more than doubled to top $65.

March 31 proved to be a major catalyst, with shares surging more than 23% after the company announced a key customer win.

Aehr said it secured a new silicon photonics customer that ordered multiple FOX-XP systems. The company described this customer as “a global leader in networking products and solutions and a major supplier to the data center optical transceiver market.”

This matters because optical transceivers are being rapidly adopted in AI data centers to move ever-larger volumes of data. Companies such as Coherent (NYSE: COHR) and Lumentum (NASDAQ: LITE), which make optical components, have seen significant share-price gains recently. For Aehr, gaining a foothold in this expanding market is a meaningful victory, and the company noted that follow-on orders are possible in 2026.

Importantly, the customer is buying systems for both engineering qualification and high-volume production. While customers typically qualify systems before ramping production, doing both simultaneously suggests confidence in Aehr’s technology and urgency on the customer’s part — both bullish signs for future orders.

Aehr Looks Poised to See Significant Growth in Fiscal 2027

In its latest quarter, Aehr reported revenue of $10.3 million, slightly below analysts’ $10.85 million estimate. The company’s loss of $0.05 per share was smaller than the $0.07 analysts expected.

Aehr reiterated guidance of $25 million to $30 million in revenue for the second half of fiscal 2026 (FY2026) and maintained an adjusted loss-per-share outlook between $0.09 and $0.05. Note that Aehr recently reported Q3 FY2026 results; its fiscal year does not align with the calendar year.

The more compelling story is forward-looking. During the quarter, Aehr recorded bookings of $37.2 million — more than 3.5 times its revenue — a strong indicator of larger revenues ahead. The company now expects second-half FY2026 bookings to come in at the high end of its $60 million to $80 million range.

Aehr’s effective backlog reached a record $50.9 million, slightly above the high end of its FY2026 revenue guidance. That backlog provides a meaningful base to support higher sales in FY2027.

AEHR Continues to Show It Is Not a Name to Ignore

Overall, Aehr continues to demonstrate an ability to win customers and orders. It has relationships with an AI-processor developer and silicon photonics developers — two areas with strong and growing demand.

The company is also in discussions with another AI processor supplier, multiple high-bandwidth memory companies, and a NAND flash supplier. These memory technologies are among the fastest-growing segments in AI infrastructure.

Valuation remains a consideration: AEHR has a market capitalization above $2 billion while expecting up to roughly $50 million in sales for FY2026. That gap makes it hard to call the stock undervalued today. At the same time, Aehr has clear growth potential in a rapidly expanding AI market. With shares having run up sharply, downside risk is real — but given the company’s recent wins, additional positive developments could push the stock higher.

After the earnings report, analysts at Craig Hallum upgraded AEHR from Hold to Buy and set a $68 price target — a level the stock surpassed soon after.

3 Bargain-Cheap Small Caps Worth a Second Look

Submitted by Chris Markoch. First Published: 4/9/2026.

The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company’s valuation. The average P/E ratio of stocks in the S&P 500 is around 27x. Any stock with a ratio below that level may offer value relative to its earnings.

To be considered a “low P/E stock,” a P/E ratio is usually between 5x and 12x. Not surprisingly, many stocks that meet that threshold tend to be smaller companies that fly under the radar of institutional investors.

URGENT: $2 Gold Stock With Major Discovery (Ad)

A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1 trillion.

According to Jim Rickards, an announcement is expected around July 1 that could bring this historic discovery into public view.

See the full details on this $2 gold stock before July 1

This may be a good time to look at low P/E small-cap stocks: many analysts believe small caps will perform well if there’s a broader market rally.

Sometimes a low P/E ratio signals a fundamental problem with a company’s business. But with the right catalysts, it can also be an opportunity to accumulate shares of companies whose growth prospects are being overlooked. This article examines three small-cap stocks with low P/E ratios and the reasons investors may want to take a closer look.

Innoviva—A Biotech With Royalties, Drugs, and a 51% Upside Case

Many biotechnology companies are small caps because they remain clinical-stage and lack commercialized drugs. When a biotech does bring a drug to market, the stock can move sharply higher.

That may be the case with Innoviva Inc. (NASDAQ: INVA). The company is somewhat unique among biotechs because of its three-part business model: a funding layer from stable, high-margin royalties on respiratory drugs developed with GSK (NYSE: GSK), its own specialty therapeutics focused on critical care and infectious diseases, and a portfolio of strategic healthcare investments.

Innoviva has shown strong year-over-year revenue and earnings growth. More significantly, the company is becoming less reliant on royalty revenue, which recently fell to 60% of total revenue from 72%.

The company recorded a one-time gain of approximately $161 million in 2025 that boosted net income. That nonrecurring gain helps explain why analysts project a 42% decline in earnings in 2026 before a return to earnings growth in 2027. Despite the projected dip, analysts have a consensus price target of $34.80 on INVA, implying roughly 50% upside from current levels.

Wendy’s—A High-Yield Dividend Play Waiting for the Consumer to Come Back

Wendy’s (NYSE: WEN) may be a case of a beaten-down stock becoming attractive. The company reported disappointing results in February, highlighted by an alarming decline in same-store sales.

Like many restaurant chains, Wendy’s is being pressured by consumers dining out less. Even lower-priced fast-food chains face headwinds as customers shift toward healthier choices or change behavior due to the impact of GLP-1 drugs.

The company is taking steps to adapt, closing underperforming restaurants and expanding internationally, where growth has been a relative bright spot.

Another potential positive is Wendy’s dividend. That yield of over 8% requires context: the high yield largely reflects a falling share price rather than a recent payout increase. Whether the dividend holds depends on several factors, some outside the company’s control.

For now, the dividend appears supported. If the economy improves and Wendy’s core customer regains spending power, accumulating WEN at current levels could produce meaningful long-term compounding.

Nabors Industries—An Oil-Driven Momentum Trade With an Earnings Catalyst Ahead

Nabors Industries (NYSE: NBR) is an example of investors riding the hot hand. The oil and gas drilling-services company’s stock has climbed sharply in 2026 alongside other energy stocks, with gains accelerating after a recent spike in oil prices.

Investors may wonder whether it’s wise to chase NBR higher. Analysts have raised price targets, but even the most optimistic targets leave limited upside from current trading levels.

That makes Nabors more speculative than the other names here, and the stock’s near-term direction may hinge on upcoming earnings: the company will report in late April.

By then there may be more clarity around tensions in the Strait of Hormuz; if those geopolitical pressures persist, oil prices could stay elevated. Even with a resolution, it could take time for markets to adjust, and demand for oil has other supportive catalysts beyond the regional conflict.

Still, oil prices could retreat as quickly as they rose. As a short-term momentum play into the next quarter, however, NBR could be an appealing, if speculative, choice.